Skip to main content

Immunologic Deficiency Syndrome

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biopharma Group
Biopharma GroupUK - Winchester
1 program
1
Immune Globulin IntravenousPhase 31 trial
Active Trials
NCT01406470Completed45Est. Jul 2013
Grifols
GrifolsNEW YORK, NY
2 programs
Immune Globulin IntravenousPHASE_21 trial
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography PurifiedPHASE_31 trial
Active Trials
NCT00389324Completed35Est. Aug 2008
NCT00220766Completed100Est. Mar 2004
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
Immune Globulin IntravenousPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Biopharma GroupImmune Globulin Intravenous
GrifolsImmune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
GrifolsImmune Globulin Intravenous

Clinical Trials (3)

Total enrollment: 180 patients across 3 trials

NCT01406470Biopharma GroupImmune Globulin Intravenous

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Start: Sep 2011Est. completion: Jul 201345 patients
Phase 3Completed
NCT00220766GrifolsImmune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Start: Aug 2002Est. completion: Mar 2004100 patients
Phase 3Completed
NCT00389324GrifolsImmune Globulin Intravenous

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Start: Nov 2006Est. completion: Aug 200835 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.